Daewoong pharmaceutical Co.,Ltd (069620.KS)
KRW 125500.0
(-2.64%)
KRW 125500.0
(-2.64%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 1770.31 Billion KRW | 13.24% |
| 2022 | 1563.34 Billion KRW | 10.47% |
| 2021 | 1415.17 Billion KRW | 3.53% |
| 2020 | 1366.9 Billion KRW | 9.73% |
| 2019 | 1245.66 Billion KRW | 3.13% |
| 2018 | 1207.84 Billion KRW | -0.47% |
| 2017 | 1213.52 Billion KRW | 6.01% |
| 2016 | 1144.69 Billion KRW | 21.19% |
| 2015 | 944.52 Billion KRW | 36.05% |
| 2014 | 694.26 Billion KRW | 19.9% |
| 2013 | 579.01 Billion KRW | 20.04% |
| 2012 | 482.34 Billion KRW | -3.23% |
| 2011 | 498.46 Billion KRW | -2.0% |
| 2010 | 508.62 Billion KRW | 2.44% |
| 2009 | 496.52 Billion KRW | 2.12% |
| 2008 | 486.23 Billion KRW | 23.79% |
| 2007 | 392.8 Billion KRW | 22.05% |
| 2006 | 321.84 Billion KRW | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 1808.47 Billion KRW | 2.16% |
| 2024 Q2 | 1877.35 Billion KRW | 3.81% |
| 2023 Q4 | 1770.31 Billion KRW | 3.58% |
| 2023 FY | 1770.31 Billion KRW | 13.24% |
| 2023 Q2 | 1646.04 Billion KRW | 0.08% |
| 2023 Q1 | 1644.67 Billion KRW | 5.2% |
| 2023 Q3 | 1709.1 Billion KRW | 3.83% |
| 2022 FY | 1563.34 Billion KRW | 10.47% |
| 2022 Q3 | 1540.15 Billion KRW | 2.89% |
| 2022 Q4 | 1563.34 Billion KRW | 1.51% |
| 2022 Q2 | 1496.94 Billion KRW | 2.82% |
| 2022 Q1 | 1455.84 Billion KRW | 2.87% |
| 2021 Q2 | 1390.39 Billion KRW | -2.18% |
| 2021 FY | 1415.17 Billion KRW | 3.53% |
| 2021 Q1 | 1421.43 Billion KRW | 3.99% |
| 2021 Q3 | 1400.32 Billion KRW | 0.71% |
| 2021 Q4 | 1415.17 Billion KRW | 1.06% |
| 2020 Q2 | 1250.48 Billion KRW | -1.89% |
| 2020 Q1 | 1274.55 Billion KRW | 2.32% |
| 2020 FY | 1366.9 Billion KRW | 9.73% |
| 2020 Q3 | 1336.49 Billion KRW | 6.88% |
| 2020 Q4 | 1366.9 Billion KRW | 2.28% |
| 2019 Q2 | 1233.03 Billion KRW | 1.42% |
| 2019 FY | 1245.66 Billion KRW | 3.13% |
| 2019 Q1 | 1215.7 Billion KRW | 0.65% |
| 2019 Q4 | 1245.66 Billion KRW | -0.01% |
| 2019 Q3 | 1245.77 Billion KRW | 1.03% |
| 2018 Q3 | 1223.82 Billion KRW | 0.05% |
| 2018 Q1 | 1215.2 Billion KRW | 0.14% |
| 2018 FY | 1207.84 Billion KRW | -0.47% |
| 2018 Q4 | 1207.84 Billion KRW | -1.31% |
| 2018 Q2 | 1223.15 Billion KRW | 0.65% |
| 2017 Q4 | 1213.52 Billion KRW | 2.27% |
| 2017 FY | 1213.52 Billion KRW | 6.01% |
| 2017 Q3 | 1186.55 Billion KRW | 2.37% |
| 2017 Q2 | 1159.12 Billion KRW | 1.58% |
| 2017 Q1 | 1141.06 Billion KRW | -0.32% |
| 2016 Q4 | 1144.69 Billion KRW | 7.24% |
| 2016 Q1 | 950.34 Billion KRW | 0.62% |
| 2016 Q2 | 1072.52 Billion KRW | 12.86% |
| 2016 FY | 1144.69 Billion KRW | 21.19% |
| 2016 Q3 | 1067.44 Billion KRW | -0.47% |
| 2015 FY | 944.52 Billion KRW | 36.05% |
| 2015 Q2 | 732.89 Billion KRW | 3.05% |
| 2015 Q3 | 958.38 Billion KRW | 30.77% |
| 2015 Q1 | 711.18 Billion KRW | 2.44% |
| 2015 Q4 | 944.52 Billion KRW | -1.45% |
| 2014 Q2 | 595.67 Billion KRW | 0.99% |
| 2014 Q3 | 614.68 Billion KRW | 3.19% |
| 2014 FY | 694.26 Billion KRW | 19.9% |
| 2014 Q4 | 694.26 Billion KRW | 12.95% |
| 2014 Q1 | 589.82 Billion KRW | 1.87% |
| 2013 FY | 579.01 Billion KRW | 20.04% |
| 2013 Q3 | 530.36 Billion KRW | 3.71% |
| 2013 Q2 | 511.39 Billion KRW | 0.07% |
| 2013 Q4 | 579.01 Billion KRW | 9.17% |
| 2013 Q1 | 511.04 Billion KRW | 5.95% |
| 2012 Q1 | 486.11 Billion KRW | 0.0% |
| 2012 Q4 | 482.34 Billion KRW | 0.0% |
| 2012 FY | 482.34 Billion KRW | -3.23% |
| 2011 Q1 | 489.91 Billion KRW | 0.0% |
| 2011 FY | 498.46 Billion KRW | -2.0% |
| 2011 Q3 | 494.51 Billion KRW | -0.85% |
| 2011 Q2 | 498.74 Billion KRW | 1.8% |
| 2010 Q1 | 496.52 Billion KRW | 3.98% |
| 2010 FY | 508.62 Billion KRW | 2.44% |
| 2010 Q2 | 518.4 Billion KRW | 4.41% |
| 2010 Q3 | 491.52 Billion KRW | -5.18% |
| 2009 Q2 | 471.69 Billion KRW | 0.0% |
| 2009 Q4 | 477.53 Billion KRW | 4.02% |
| 2009 Q3 | 459.08 Billion KRW | -2.67% |
| 2009 FY | 496.52 Billion KRW | 2.12% |
| 2008 Q3 | 462.14 Billion KRW | 10.65% |
| 2008 Q2 | 417.67 Billion KRW | 0.0% |
| 2008 Q4 | 485.34 Billion KRW | 5.02% |
| 2008 FY | 486.23 Billion KRW | 23.79% |
| 2007 FY | 392.8 Billion KRW | 22.05% |
| 2007 Q2 | 326.48 Billion KRW | 0.0% |
| 2007 Q4 | 354.53 Billion KRW | 5.17% |
| 2007 Q3 | 337.1 Billion KRW | 3.25% |
| 2006 FY | 321.84 Billion KRW | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 198.21 Billion KRW | -793.133% |
| Dong-A Socio Holdings Co., Ltd. | 1957.1 Billion KRW | 9.544% |
| Ildong Holdings Co., Ltd. | 876.99 Billion KRW | -101.86% |
| HANDOK Inc. | 790.33 Billion KRW | -123.994% |
| Kukje Pharma Co., Ltd. | 170.61 Billion KRW | -937.576% |
| Yuhan Corporation | 2814.07 Billion KRW | 37.091% |
| Dong-A ST Co., Ltd. | 1315.21 Billion KRW | -34.602% |
| SAMSUNG PHARM. Co., LTD. | 93.47 Billion KRW | -1793.805% |
| Hanmi Pharm. Co., Ltd. | 1952.03 Billion KRW | 9.309% |
| Hanall Biopharma Co.,Ltd | 239.74 Billion KRW | -638.408% |
| Ilyang Pharmaceutical Co.,Ltd | 468.9 Billion KRW | -277.543% |
| Dong Sung Bio Pharm.Co.,Ltd. | 114.97 Billion KRW | -1439.758% |
| MYUNGMOON Pharm co.,Ltd | 236.54 Billion KRW | -648.391% |
| Hana Pharm Co., Ltd. | 348.38 Billion KRW | -408.146% |
| Yuyu Pharma, Inc. | 198.21 Billion KRW | -793.133% |
| Ilsung Pharmaceuticals Co., Ltd. | 419.18 Billion KRW | -322.317% |
| REYON Pharmaceutical Co., Ltd. | 499.77 Billion KRW | -254.221% |
| Aprogen pharmaceuticals,Inc. | 589.39 Billion KRW | -200.36% |
| JW Holdings Corporation | 1176.26 Billion KRW | -50.503% |
| Ildong Pharmaceutical Co., Ltd. | 611.26 Billion KRW | -189.616% |
| Chong Kun Dang Pharmaceutical Corp. | 1402.42 Billion KRW | -26.232% |
| JW Pharmaceutical Corporation | 645.03 Billion KRW | -174.45% |
| Shin Poong Pharm.Co.,Ltd. | 350.08 Billion KRW | -405.682% |
| Hyundai Pharmaceutical Co., Ltd. | 154.04 Billion KRW | -1049.246% |
| Samil Pharmaceutical Co.,Ltd | 370.68 Billion KRW | -377.585% |
| Jeil Pharmaceutical Co.,Ltd | 487.32 Billion KRW | -263.27% |
| Yuyu Pharma, Inc. | 198.21 Billion KRW | -793.133% |
| Kwang Dong Pharmaceutical Co., Ltd. | 1078.06 Billion KRW | -64.212% |
| JW Pharmaceutical Corporation | 645.03 Billion KRW | -174.45% |
| Yuhan Corporation | 2814.07 Billion KRW | 37.091% |
| Jeil Pharma Holdings Inc | 879.99 Billion KRW | -101.172% |
| Yungjin Pharm. Co., Ltd. | 226.6 Billion KRW | -681.246% |
| Suheung Co., Ltd. | 993.73 Billion KRW | -78.147% |
| JW Pharmaceutical Corporation | 645.03 Billion KRW | -174.45% |
| Samjin Pharmaceuticals Co., Ltd. | 419.9 Billion KRW | -321.602% |
| Korea United Pharm Inc. | 468.86 Billion KRW | -277.577% |
| CKD Bio Corp. | 293.78 Billion KRW | -502.587% |
| Daewon Pharmaceutical Co., Ltd. | 507.99 Billion KRW | -248.488% |
| Dongwha Pharm.Co.,Ltd | 564.97 Billion KRW | -213.345% |
| Whan In Pharm Co.,Ltd. | 401.22 Billion KRW | -341.225% |
| Shin Poong Pharm.Co.,Ltd. | 350.08 Billion KRW | -405.682% |
| Chong Kun Dang Holdings Corp. | 1456 Billion KRW | -21.587% |
| Boryung Corporation | 922.36 Billion KRW | -91.932% |
| Bukwang Pharmaceutical Co., Ltd. | 442.46 Billion KRW | -300.105% |
| Ilyang Pharmaceutical Co.,Ltd | 468.9 Billion KRW | -277.543% |
| JW Lifescience Corporation | 255.83 Billion KRW | -591.97% |